Pulse Biosciences, Inc.

PLSE

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001625101

D

fourth fifth of 369 graded peers in healthcare

rank 241 of 369; percentile 65.2; sampling error 2.5 points; lower is stronger

A B C D E


D, the sloth



Scoreboard


Profitability	C/D percentile 62.0
Solvency	B percentile 34.2
Growth and financing	D percentile 63.9
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $94.5M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Apr 30, 2026 194 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$58.10 2026-11-09; market equity $4.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation ("NPS") technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation ("nsPFA") technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 62.0						
Gross profitability	(0.2%)	32.3%		97.3	365	2025-12-31
Return on invested capital	not computable	9.3%				


one or more required annual facts are missing

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(16.4%)	(6.6%)	26.8	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 4					
Solvency, sleeve percentile 34.2					
Twelve-month failure probability	0.04%	0.08%	25.5	248	2026-09-30
Altman Z double-prime	(10.11)	(0.35)	62.2	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	10.53x	2.95x	14.9	826	2025-12-31
Growth and financing, sleeve percentile 63.9					
Revenue growth, three-year compound	(20.6%)	10.1%	89.8	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	6.7%	2.2%	38.0	694	2025-12-31
Net share issuance, one year	not computable	2.5%			
prior share count is 46 days earlier					

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
236	Organogenesis Holdings Inc. (ORGO)	63.9	D	fortress balance sheet
237	Arvinas, Inc. (ARVN)	64.1	D	fortress balance sheet
238	Perspective Therapeutics, Inc. (CATX)	64.4	D	dilution, short runway, fortress balance sheet
239	Cardiff Oncology, Inc. (CRDF)	64.7	D	short runway, fortress balance sheet
240	Entera Bio Ltd. (ENTX)	64.9	D	degenerate inputs
241	Pulse Biosciences, Inc. (PLSE)	65.2	D	
242	Lenz Therapeutics, Inc. (LENZ)	65.5	D	short runway
243	Fulgent Genetics, Inc. (FLGT)	65.8	D	
244	Dentsply Sirona Inc. (XRAY)	66.0	D	
245	AIM ImmunoTech Inc. (AIM)	66.3	D	late filer, degenerate inputs, distress
246	Angiodynamics Inc. (ANGO)	66.6	D	fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	194.9%	(1.9%)	96
Distance from 52-week high	0.0%	(27.5%)	90
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(1.3%)	(1.0%)	49
Book value to price	0.04	0.27	17
Sales to price	0.00	0.29	1
Composite equity issuance, five years	103.7%	20.8%	77
Relative strength against the sector, log excess return	0.91	(0.19)	96

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$36.7M
Operating cash flow, four quarters	-$63.3M
Months of runway	7.0
Days since last periodic filing	5 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$22.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$350,000	2025-12-31	2026-02-19	10-K	26-004724
2	cost of revenue	us-gaap:CostOfRevenue	$539,000	2025-12-31	2026-02-19	10-K	26-004724
3	assets	us-gaap:Assets	$94.5M	2025-12-31	2026-02-19	10-K	26-004724
4	net income	us-gaap:NetIncomeLoss	-$72.8M	2025-12-31	2026-02-19	10-K	26-004724
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$54.1M	2025-12-31	2026-02-19	10-K	26-004724
6	assets	us-gaap:Assets	$132.5M	2024-12-31	2026-02-19	10-K	26-004724
7	current assets	us-gaap:AssetsCurrent	$83.4M	2025-12-31	2026-02-19	10-K	26-004724
8	current liabilities	us-gaap:LiabilitiesCurrent	$7.9M	2025-12-31	2026-02-19	10-K	26-004724
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$463.3M	2025-12-31	2026-02-19	10-K	26-004724
10	operating income	us-gaap:OperatingIncomeLoss	-$76.9M	2025-12-31	2026-02-19	10-K	26-004724
11	book equity	us-gaap:StockholdersEquity	$80.7M	2025-12-31	2026-02-19	10-K	26-004724
12	liabilities	us-gaap:Liabilities	$13.9M	2025-12-31	2026-02-19	10-K	26-004724
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2024-12-31	2026-02-19	10-K	26-004724
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2023-12-31	2025-03-31	10-K	25-009932
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$700,000	2022-12-31	2024-03-28	10-K	24-009815
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$315,000	2025-12-31	2026-02-19	10-K	26-004724
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$36.3M	2024-12-31	2026-02-19	10-K	26-004724
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$125,000	2024-12-31	2026-02-19	10-K	26-004724

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$33.0M	2023-12-31	2025-03-31	10-K	25-009932
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$121,000	2023-12-31	2025-03-31	10-K	25-009932
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$47.0M	2022-12-31	2024-03-28	10-K	24-009815
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$401,000	2022-12-31	2024-03-28	10-K	24-009815
23	depreciation amortization	us-gaap:Depreciation	$406,000	2025-12-31	2026-02-19	10-K	26-004724
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$72.8M	2025-12-31	2026-02-19	10-K	26-004724
25	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-02-19	10-K	26-004724
26	current assets	us-gaap:AssetsCurrent	$119.4M	2024-12-31	2026-02-19	10-K	26-004724
27	current liabilities	us-gaap:LiabilitiesCurrent	$10.1M	2024-12-31	2026-02-19	10-K	26-004724
28	assets	us-gaap:Assets	$59.2M	2023-12-31	2025-03-31	10-K	25-009932
29	assets	us-gaap:Assets	$77.9M	2022-12-31	2024-03-28	10-K	24-009815
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,225,067	2026-03-31	2026-04-30	10-K/A	26-014203
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	67,989,078	2026-02-13	2026-02-19	10-K	26-004724

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.